- Medical Departments & Centers
- Infectious Diseases
- Clinical trials
Below are current clinical trials.
Filter this list of studies by location, status and more.
COVID-19 and Acute Renal Failure
Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Rochester, Minn.
The primary purpose of this study is to examine 1-year survival and rate of secondary infections in COVID-19 patients with and without acute kidney injury (AKI).
A Study of Nervous System Involvement of Coccidioidomycosis at Mayo Clinic Hospital in Arizona
Scottsdale/Phoenix, Ariz.
The purpose of this study is to gain a better understanding of the presentation, diagnostics, disease course and treatment variations, as well as the factors that may influence features of neuro-invasive Coccidioidomycosis.
Genetic Expression in Osteolysis, Infection, Arthrofibrosis & Metal Reactions in THA & TKA: A Microarray Analysis to Characterize Individual Host Response to the Molecular Mechanisms of Loosening and Arthrofibrosis
Rochester, Minn.
This study is being conducted to determine gene and protein expression profiles (i.e. which genes and proteins are turned off and on) of those with a possibility of developing osteolysis, infection, arthrofibrosis or metallosis of their THA/TKA.
Laboratory Assay Optimization 2.0
The purpose of this study is to better understand the role of HIV and/or HCV infection and/or SARS-CoV-2 on the immune system and potential ways to eliminate the virus(es).
Detection of Infection in Arthroplasty
The purpose of this study is to determine the sensitivity, specificity, positive and negative predictive values of molecular detection of microorganisms, detection of microbial proteins and antibodies against microorganisms, and inflammatory markers (e.g., leukocyte esterase, CRP) in synovial fluid for the diagnosis of prosthetic joint infection (PJI).
NSITE: Novel Strategies to Increase Telehealth Engagement
Eau Claire, Wis., Rochester, Minn.
The primary objective of Aim 1 of this study are to identify personal and social determinant of health-related key factors that present as a barriers to use of non-emergent telehealth care during the COVID-19 pandemic. Aim 1 will use a qualitative study design to understand the experiences of patients along with social determinants of health (SDOH). The results of the qualitative work will be used by the research team to design the survey for administration in Aim 2.
The primary objectgive of Aim 2 of this study is to assess personal and social determinants of health that are associated with patient’s decision to prefer face-to-face visits compared with telehealth appointments for non-emergent care.
Study Using Clofazimine to Treat Patients with Non-Tuberculous Mycobacterial Infections
The purpose of this study is to determine whether adding clofazimine in a treatment regimen for patients with non-tuberculous mycobacterial (NTM) infections will improve low clinical success rates in NTM infections, its mode of action, and literature reported clinical data in both NTM and multidrug-resistant tuberculosis.
A Study to Assess International SARS-CoV-2 (COVID-19) Infection
T cell response to covid19 vaccinated individuals.
Rochester, Minn., Jacksonville, Fla.
The first aim of this study is to verify that the TCR beta sequencing and curation platforms we will be using are able to identify patients with severe COVID-19 based on the TCR repertoires. This may be accomplished by testing and analyzing results between two cohorts: patients presenting acutely to MCF with mild COVID-19 and patients presenting with severe COVID-19. This will be accomplished by utilizing the the immunoSEQ Human T-cell Receptor Beta (hsTCB) Assay (Adaptive Biothechnologies) and the publicly available ImmuneCODE Open Access Database to confirm previously published data (PMID: 34253751). Both procedures will be performed by the company that created both platforms, Adaptive Biothechnologies.
The second aim of this study is to sequence the TCR receptors of participating patients and identify TCR motifs that may indicate a predisposition to (or protection from) severe SARS-CoV-2, leading to possible risk stratification of such patients, and whether or not age, gender or ethnicity has any contribution to said risk. This may require that we examine all three cohorts listed in the Subject Information section.
The third aim is to measure SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies to distinguish patients that have not been exposed to SARS-CoV-2 to those that have been exposed.
Evaluation of the Effects of Caffeine, Via the ACE2 Receptor, on Clinical Severity of COVID-19 Disease
Jacksonville, Fla.
The purpose of this study is to assess levels of caffeine intake among patients who tested positive for COVID-19 infection and compare that to disease severity.
- Tests & procedures
- Conditions treated
- Specialty groups
- Expertise & rankings
- Patient stories
- Costs & insurance
- News from Mayo Clinic
Research: It's all about patients
[MUSIC PLAYING]
Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight.
- Request an Appointment
5X Challenge
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.
Division of Infectious Diseases section navigation
Infectious diseases research.
The Division of Infectious Diseases engages in a broad spectrum of basic, clinical, translational, and epidemiologic sciences. The division garners more than $30 million in research funding per year.
Infectious Diseases faculty collaborate actively with other top-rated local and regional programs, including the Emory Vaccine Center , the Emory Department of Microbiology and Immunology , the Emory Rollins School of Public Health , and the Centers for Disease Control and Prevention (CDC) , in addition to numerous centers in the United States and abroad.
You can view ongoing trials in Infectious Diseases by visiting Emory Clinical Trials .
Research Programs
- Antibiotic Resistance Center
- Center for AIDS Research
- Kwazulu-Natal Drug Resistance Surveillance Study
- Emerging Infections Program
- Emory Clinical Trials Unit
- Emory T32 Training Program in Translational Research to End the HIV Epidemic
- Hope Clinic - Vaccine Research
- Prevention Epicenter of Emory and Collaborating Healthcare Facilities (PEACH)
- Ponce Clinical Research Site
- Infectious Diseases Clinical Research Collaborative
- Integrating HIV and heart health in South Africa (iHEART-SA) project
- Research in HIV and Women's Health and Y This Harmony Matters (RHYTHM)
Basic Science Research Opportunities
Basic scientific research within the Division of Infectious Diseases focuses on:
- Mechanisms and control of antibiotic resistance
- Treatment of hospital-acquired infections, such as Clostridium difficile ( C. difficile )
- Pathogenesis of infectious diseases, such as bacterial meningitis
- Basic and translational research in HIV
- Immunology of host defenses and vaccine development
Major areas of investigation of bacterial pathogens include:
- Analysis of virulence mechanisms of invasive bacterial pathogens
- The role of endogenous bacterial CRISPR/Cas9 systems in host immune evasion and targeted DNA editing
- Genomics of bacterial virulence and antibiotic resistance; study of the microbiome
- Studies of the molecular mechanisms of antibiotic resistance
- Research into the role of transposable elements and repetitive nucleotide sequences in microbial pathogenesis and agents associated with bioterrorism
- Metagenomics of pathogens for basic and clinical research
The Division of Infectious Diseases participates in graduate programs and research in microbiology and molecular genetics, immunology and molecular pathogenesis, as well as population biology, ecology, and evolution.
Additional opportunities are available for basic science research in:
- Toxin-mediated infections
- Intracellular pathogens
- Hemorrhagic fever viruses
- Zoonotic pathogens
- Parasites and fungi
- Population biology
- Genomics and metagenomics
Emory Vaccine Center and Emory Hope Clinic
The Emory Vaccine Center receives more than $24 million in sponsored research funding. Primary program areas in basic science and translational research currently include HIV/AIDS, tuberculosis, malaria, Hepatitis C virus (HCV), cytomegalovirus, gamma-herpes viruses, influenza and DNA and protein-conjugate vaccines.
The Hope Clinic , a unit of the Emory Vaccine Center directed by Mark Mulligan, MD, conducts clinical research, vaccine trials and critical research on vaccine policies. A number of additional opportunities for basic scientific research are available in the Graduate Divisions of Microbiology and Immunology and through the Centers for Disease Control .
Clinical and Diagnostic Microbiology
Emory University Hospital and Grady Memorial Hospital have outstanding resources in diagnostic and clinical microbiology.
Areas of focus include:
- Development and assessment of diagnostic tools based on nucleic acid detection
- Optimization of laboratory procedures for diagnosis of mycobacterial infections
- Assessment of the accuracy of automated systems for detection of antimicrobial resistance
Clinical/Translational Research Opportunities and Global Health
Major areas of focus for clinical/translational research in infectious diseases include:
- HIV/AIDS; access to and retention in care
- Sexually transmitted infections
- C. difficile infections; prevention and treatment modalities
- Tuberculosis
- Vaccine research
- Healthcare epidemiology and healthcare infections
- Transplant Infectious Diseases
- Emerging infectious diseases
- Global health
- Bioterrorism
Clinical research training opportunities are enhanced by the presence of Clinical Interaction Sites at the Emory-affiliated hospitals .
In addition, opportunities for clinical and translational research training are enhanced by the presence of the NIH-funded CTSA award ( Georgia Clinical and Translational Science Alliance , or CTSA) which was awarded to Emory University in collaboration with Morehouse School of Medicine and the Georgia Institute of Technology. A major component of the ACTSI is the Research Education, Training and Career Development program, which includes the Master of Science in Clinical Research (MSCR).
Clinical Infectious Diseases Study Guide
A Problem-Based Approach
- © 2020
- Joseph Domachowske 0 ,
- Manika Suryadevara 1
Department of Pediatrics, SUNY Upstate Medical University, Syracuse, USA
You can also search for this author in PubMed Google Scholar
- The only study guide that is current on basic infections disease fundamentals
- Written by experts in both adult and pediatric infections
- Each chapter follows a consistent format for ease of use
- Can serve as a standalone book or as a complement to a larger book accompanying a course, such as Introduction to Clinical Infectious Diseases
- The chapters and writing style parallel the larger textbook with an additional 15 topics covered
64k Accesses
2 Citations
5 Altmetric
This is a preview of subscription content, log in via an institution to check access.
Access this book
Subscribe and save.
- Get 10 units per month
- Download Article/Chapter or eBook
- 1 Unit = 1 Article or 1 Chapter
- Cancel anytime
- Available as EPUB and PDF
- Read on any device
- Instant download
- Own it forever
- Compact, lightweight edition
- Dispatched in 3 to 5 business days
- Free shipping worldwide - see info
Tax calculation will be finalised at checkout
Other ways to access
Licence this eBook for your library
Institutional subscriptions
About this book
Similar content being viewed by others.
Infectious Diseases
Infectious Disease
Person-Centered Infectious Diseases and Pandemics
- Diagnostic microbiology
- Tropical infections of global importance
- Infections of the central nervous system
- Fundamentals of infectious diseases
- Infections of the respiratory tract
- infectious diseases
Table of contents (58 chapters)
Front matter, bacterial infections of skin and skin structures.
Joseph Domachowske, Manika Suryadevara
Febrile Exanthems of Childhood
Acute and chronic lymphadenitis, endophthalmitis, otitis, sinusitis, and mastoiditis, pharyngitis and pharyngeal space infections, pertussis and pertussis syndrome, laryngitis, tracheitis, epiglottitis, and bronchiolitis, community-acquired pneumonia, influenza infection, tuberculosis, atypical pneumonia, fungal pneumonia, infective endocarditis, infectious myocarditis, acute rheumatic fever, kawasaki disease, infectious hepatitis, authors and affiliations, about the authors, bibliographic information.
Book Title : Clinical Infectious Diseases Study Guide
Book Subtitle : A Problem-Based Approach
Authors : Joseph Domachowske, Manika Suryadevara
DOI : https://doi.org/10.1007/978-3-030-50873-9
Publisher : Springer Cham
eBook Packages : Medicine , Medicine (R0)
Copyright Information : The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2020
Softcover ISBN : 978-3-030-50872-2 Published: 06 August 2020
eBook ISBN : 978-3-030-50873-9 Published: 05 August 2020
Edition Number : 1
Number of Pages : IX, 380
Number of Illustrations : 27 b/w illustrations, 32 illustrations in colour
Topics : Infectious Diseases , Medical Microbiology , General Practice / Family Medicine , Pediatrics
- Publish with us
Policies and ethics
- Find a journal
- Track your research
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
- View all journals
- Explore content
- About the journal
- Publish with us
- Sign up for alerts
- Review Article
- Published: 14 February 2020
A systems approach to infectious disease
- Manon Eckhardt 1 , 2 , 3 na1 ,
- Judd F. Hultquist 1 , 2 , 3 , 4 na1 ,
- Robyn M. Kaake 1 , 2 , 3 ,
- Ruth Hüttenhain 1 , 2 , 3 &
- Nevan J. Krogan ORCID: orcid.org/0000-0003-4902-337X 1 , 2 , 3
Nature Reviews Genetics volume 21 , pages 339–354 ( 2020 ) Cite this article
10k Accesses
70 Citations
85 Altmetric
Metrics details
- Gene regulatory networks
- Infectious diseases
- Regulatory networks
- Systems biology
Ongoing social, political and ecological changes in the 21st century have placed more people at risk of life-threatening acute and chronic infections than ever before. The development of new diagnostic, prophylactic, therapeutic and curative strategies is critical to address this burden but is predicated on a detailed understanding of the immensely complex relationship between pathogens and their hosts. Traditional, reductionist approaches to investigate this dynamic often lack the scale and/or scope to faithfully model the dual and co-dependent nature of this relationship, limiting the success of translational efforts. With recent advances in large-scale, quantitative omics methods as well as in integrative analytical strategies, systems biology approaches for the study of infectious disease are quickly forming a new paradigm for how we understand and model host–pathogen relationships for translational applications. Here, we delineate a framework for a systems biology approach to infectious disease in three parts: discovery — the design, collection and analysis of omics data; representation — the iterative modelling, integration and visualization of complex data sets; and application — the interpretation and hypothesis-based inquiry towards translational outcomes.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
176,64 € per year
only 14,72 € per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Modelling microbial infection to address global health challenges
A compendium of multi-omics data illuminating host responses to lethal human virus infections
Host genetics and infectious disease: new tools, insights and translational opportunities
World Health Organization. WHO global health estimates 2016: disease burden by cause, age, sex, by country and by region, 2000–2016 (WHO, 2018).
Aderem, A. et al. A systems biology approach to infectious disease research: innovating the pathogen-host research paradigm. mBio 2 , e00325–e00410 (2011).
Article PubMed PubMed Central Google Scholar
Hillmer, R. A. Systems biology for biologists. PLoS Pathog. 11 , e1004786 (2015). An approachable introduction to systems biology for experimentalists .
Article PubMed PubMed Central CAS Google Scholar
Kitano, H. Systems biology: a brief overview. Science 295 , 1662–1664 (2002). A foundational introduction to the principles of systems biology .
Article CAS PubMed Google Scholar
Ideker, T., Galitski, T. & Hood, L. A new approach to decoding life: systems biology. Annu. Rev. Genomics Hum. Genet. 2 , 343–372 (2001).
Casadevall, A. & Pirofski, L. A. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67 , 3703–3713 (1999).
Article CAS PubMed PubMed Central Google Scholar
Fischbach, M. A. & Krogan, N. J. The next frontier of systems biology: higher-order and interspecies interactions. Genome Biol. 11 , 208 (2010).
[No authors listed] Pathogenesis: of host and pathogen. Nat. Immunol . 7 , 217 (2006).
Westerhoff, H. V. & Palsson, B. O. The evolution of molecular biology into systems biology. Nat. Biotechnol. 22 , 1249–1252 (2004).
Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18 , 83 (2017).
Vidova, V. & Spacil, Z. A review on mass spectrometry-based quantitative proteomics: Targeted and data independent acquisition. Anal. Chim. Acta 964 , 7–23 (2017).
Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537 , 347–355 (2016).
Bensimon, A., Heck, A. J. & Aebersold, R. Mass spectrometry-based proteomics and network biology. Annu. Rev. Biochem. 81 , 379–405 (2012).
Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory epigenome. Nat. Rev. Genet. 20 , 207–220 (2019).
Rinschen, M. M., Ivanisevic, J., Giera, M. & Siuzdak, G. Identification of bioactive metabolites using activity metabolomics. Nat. Rev. Mol. Cell Biol. 20 , 353–367 (2019).
Doench, J. G. Am I ready for CRISPR? A user’s guide to genetic screens. Nat. Rev. Genet. 19 , 67–80 (2018).
Johnson, C. H., Ivanisevic, J. & Siuzdak, G. Metabolomics: beyond biomarkers and towards mechanisms. Nat. Rev. Mol. Cell Biol. 17 , 451–459 (2016).
Needham, E. J., Parker, B. L., Burykin, T., James, D. E. & Humphrey, S. J. Illuminating the dark phosphoproteome. Sci. Signal. 12 , eaau8645 (2019).
Saliba, A. E., Vonkova, I. & Gavin, A. C. The systematic analysis of protein-lipid interactions comes of age. Nat. Rev. Mol. Cell Biol. 16 , 753–761 (2015).
Wang, D. & Bodovitz, S. Single cell analysis: the new frontier in ‘omics’. Trends Biotechnol. 28 , 281–290 (2010).
Goodwin, S., McPherson, J. D. & McCombie, W. R. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 17 , 333–351 (2016).
Ideker, T. & Krogan, N. J. Differential network biology. Mol. Syst. Biol. 8 , 565 (2012).
Greco, T. M. & Cristea, I. M. Proteomics tracing the footsteps of infectious disease. Mol. Cell Proteom. 16 , S5–S14 (2017).
Article Google Scholar
Jean Beltran, P. M., Federspiel, J. D., Sheng, X. & Cristea, I. M. Proteomics and integrative omic approaches for understanding host-pathogen interactions and infectious diseases. Mol. Syst. Biol. 13 , 922 (2017).
Oxford, K. L. et al. The landscape of viral proteomics and its potential to impact human health. Expert. Rev. Proteomics 13 , 579–591 (2016).
Shah, P. S., Wojcechowskyj, J. A., Eckhardt, M. & Krogan, N. J. Comparative mapping of host-pathogen protein-protein interactions. Curr. Opin. Microbiol. 27 , 62–68 (2015).
Puschnik, A. S., Majzoub, K., Ooi, Y. S. & Carette, J. E. A CRISPR toolbox to study virus-host interactions. Nat. Rev. Microbiol. 15 , 351–364 (2017).
Grubaugh, N. D. et al. Tracking virus outbreaks in the twenty-first century. Nat. Microbiol. 4 , 10–19 (2019).
Houldcroft, C. J., Beale, M. A. & Breuer, J. Clinical and biological insights from viral genome sequencing. Nat. Rev. Microbiol. 15 , 183–192 (2017).
Newsom, S. N. & McCall, L. I. Metabolomics: Eavesdropping on silent conversations between hosts and their unwelcome guests. PLoS Pathog. 14 , e1006926 (2018).
Bernstein, B. E. et al. The NIH roadmap epigenomics mapping consortium. Nat. Biotechnol. 28 , 1045–1048 (2010).
Legrain, P. et al. The human proteome project: current state and future direction. Mol. Cell. Proteomics 10 , M111.009993 (2011).
Lander, E. S. Initial impact of the sequencing of the human genome. Nature 470 , 187–197 (2011).
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 5 , 621–628 (2008). Pioneering work demonstrating the use of RNA sequencing to quantify changes in the mammalian transcriptome .
Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 , 431–437 (2004).
Paddison, P. J. et al. A resource for large-scale RNA-interference-based screens in mammals. Nature 428 , 427–431 (2004).
Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343 , 80–84 (2014).
Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343 , 84–87 (2014).
Pan, C., Kumar, C., Bohl, S., Klingmueller, U. & Mann, M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol. Cell. Proteomics 8 , 443–450 (2009).
Sandberg, R. & Ernberg, I. The molecular portrait of in vitro growth by meta-analysis of gene-expression profiles. Genome Biol. 6 , R65 (2005).
Ross, D. T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24 , 227–235 (2000).
Fux, C. A., Shirtliff, M., Stoodley, P. & Costerton, J. W. Can laboratory reference strains mirror “real-world” pathogenesis? Trends Microbiol. 13 , 58–63 (2005).
Jenkins, J. What is the key best practice for collaborating with a computational biologist? Cell Syst. 3 , 7–11 (2016).
Article CAS Google Scholar
Lapatas, V., Stefanidakis, M., Jimenez, R. C., Via, A. & Schneider, M. V. Data integration in biological research: an overview. J. Biol. Res. 22 , 9 (2015).
Google Scholar
Elde, N. C. et al. Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. Cell 150 , 831–841 (2012).
Rauch, B. J. et al. Inhibition of CRISPR-Cas9 with bacteriophage proteins. Cell 168 , 150–158.e10 (2017).
Weekes, M. P. et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157 , 1460–1472 (2014).
Huttenhain, R. et al. ARIH2 is a Vif-dependent regulator of CUL5-mediated APOBEC3G degradation in HIV infection. Cell Host Microbe 26 , 86–99.e7 (2019).
Jean Beltran, P. M., Mathias, R. A. & Cristea, I. M. A portrait of the human organelle proteome in space and time during cytomegalovirus infection. Cell Syst. 3 , 361–373.e6 (2016).
Holgate, S. A. How to collaborate. Science https://www.sciencemag.org/careers/2012/07/how-collaborate (2012).
Du, Y. et al. Genome-wide identification of interferon-sensitive mutations enables influenza vaccine design. Science 359 , 290–296 (2018). A systems analysis of interferon sensitivity in influenza A viruses made possible by the design of new vaccine approaches, with proof of principle in animal models .
Elde, N. C., Child, S. J., Geballe, A. P. & Malik, H. S. Protein kinase R reveals an evolutionary model for defeating viral mimicry. Nature 457 , 485–489 (2009).
Collins, J. et al. Dietary trehalose enhances virulence of epidemic Clostridium difficile. Nature 553 , 291–294 (2018).
Carey, A. F. et al. TnSeq of Mycobacterium tuberculosis clinical isolates reveals strain-specific antibiotic liabilities. PLoS Pathog. 14 , e1006939 (2018).
Integrative, H. M. P. R. N. C. The integrative human microbiome project. Nature 569 , 641–648 (2019).
Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86 , 367–377 (1996). An early example of population genomics in infectious disease; this is the first report of the Δ32 mutation in human CCR5 conferring natural resistance to HIV-1 infection .
Bryant, J. M. et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 381 , 1551–1560 (2013).
Bengsch, B. et al. Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells. Immunity 48 , 1029–1045.e5 (2018).
Hamdane, N. et al. HCV-induced epigenetic changes associated with liver cancer risk persist after sustained virologic response. Gastroenterology 156 , 2313–2329.e7 (2019).
Article PubMed Google Scholar
Kennedy, E. M. et al. Posttranscriptional m(6)A editing of HIV-1 mRNAs enhances viral gene expression. Cell Host Microbe 22 , 830 (2017).
Arvey, A. et al. An atlas of the Epstein-Barr virus transcriptome and epigenome reveals host-virus regulatory interactions. Cell Host Microbe 12 , 233–245 (2012).
Jeng, E. E. et al. Systematic identification of host cell regulators of Legionella pneumophila pathogenesis using a genome-wide CRISPR screen. Cell Host Microbe 26 , 551–563.e6 (2019).
Pillay, S. et al. An essential receptor for adeno-associated virus infection. Nature 530 , 108–112 (2016).
Marceau, C. D. et al. Genetic dissection of Flaviviridae host factors through genome-scale CRISPR screens. Nature 535 , 159–163 (2016).
Hultquist, J. F. et al. A Cas9 ribonucleoprotein platform for functional genetic studies of HIV-host interactions in primary human T cells. Cell Rep. 17 , 1438–1452 (2016).
Park, R. J. et al. A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nat. Genet. 49 , 193–203 (2017).
Hoffmann, H. H. et al. Diverse viruses require the calcium transporter SPCA1 for maturation and spread. Cell Host Microbe 22 , 460–470.e5 (2017).
Korbee, C. J. et al. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nat. Commun. 9 , 358 (2018).
Zhou, P. et al. Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose. Nature 561 , 122–126 (2018). A host- and pathogen-based systems approach allows the paired identification of a new bacterial pathogen-associated molecular pattern and its receptor in human cells .
Patrick, K. L. et al. Quantitative yeast genetic interaction profiling of bacterial effector proteins uncovers a role for the human retromer in salmonella infection. Cell Syst. 7 , 323–338 e326 (2018).
Ramage, H. R. et al. A combined proteomics/genomics approach links hepatitis C virus infection with nonsense-mediated mRNA decay. Mol. Cell 57 , 329–340 (2015).
Hultquist, J. F. et al. CRISPR-Cas9 genome engineering of primary CD4 + T cells for the interrogation of HIV-host factor interactions. Nat. Protoc. 14 , 1–27 (2019).
Brass, A. L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319 , 921–926 (2008). A pioneering, RNA interference-based, functional genomics screen for the identification of host factors required for HIV-1 replication in human cells .
Michlmayr, D. et al. Comprehensive innate immune profiling of chikungunya virus infection in pediatric cases. Mol. Syst. Biol. 14 , e7862 (2018).
Thompson, E. G. et al. Host blood RNA signatures predict the outcome of tuberculosis treatment. Tuberculosis 107 , 48–58 (2017).
Sychev, Z. E. et al. Integrated systems biology analysis of KSHV latent infection reveals viral induction and reliance on peroxisome mediated lipid metabolism. PLoS Pathog. 13 , e1006256 (2017).
Lupberger, J. et al. Combined analysis of metabolomes, proteomes, and transcriptomes of hepatitis C virus-infected cells and liver to identify pathways associated with disease development. Gastroenterology 157 , 537–551 e539 (2019).
Bradley, T., Ferrari, G., Haynes, B. F., Margolis, D. M. & Browne, E. P. Single-cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency. Cell Rep. 25 , 107–117.e3 (2018).
Russell, A. B., Trapnell, C. & Bloom, J. D. Extreme heterogeneity of influenza virus infection in single cells. eLife 7 , e32303 (2018).
Diep, J. et al. Enterovirus pathogenesis requires the host methyltransferase SETD3. Nat. Microbiol. 4 , 2523–2537 (2019). A combined functional genomics and proteomics approach allows the identification of a new enterovirus host factor, with validation in primary human cells and translationally focused extension into an animal model .
Shah, P. S. et al. Comparative flavivirus-host protein interaction mapping reveals mechanisms of dengue and zika virus pathogenesis. Cell 175 , 1931–1945.e18 (2018).
Tripathi, S. et al. Meta- and orthogonal integration of influenza “OMICs” data defines a role for UBR4 in virus budding. Cell Host Microbe 18 , 723–735 (2015).
Mirrashidi, K. M. et al. Global mapping of the Inc-human interactome reveals that retromer restricts chlamydia infection. Cell Host Microbe 18 , 109–121 (2015).
Jager, S. et al. Global landscape of HIV-human protein complexes. Nature 481 , 365–370 (2011). A pioneering study systematically identifying the physical interactions of all HIV-1 proteins and polyproteins with host proteins using affinity tagging and purification mass spectrometry .
Penn, B. H. et al. An Mtb-human protein-protein interaction map identifies a switch between host antiviral and antibacterial responses. Mol. Cell 71 , 637–648.e5 (2018).
Davis, Z. H. et al. Global mapping of herpesvirus-host protein complexes reveals a transcription strategy for late genes. Mol. Cell 57 , 349–360 (2015).
Kane, J. R. et al. Lineage-specific viral hijacking of non-canonical E3 ubiquitin ligase cofactors in the evolution of Vif anti-APOBEC3 activity. Cell Rep. 11 , 1236–1250 (2015).
Babu, M. et al. Global landscape of cell envelope protein complexes in Escherichia coli. Nat. Biotechnol. 36 , 103–112 (2018).
Batra, J. et al. Protein interaction mapping identifies RBBP6 as a negative regulator of Ebola virus replication. Cell 175 , 1917–1930.e13 (2018).
Eckhardt, M. et al. Multiple routes to oncogenesis are promoted by the human papillomavirus-host protein network. Cancer Discov. 8 , 1474–1489 (2018).
Zampieri, M. et al. High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds. Sci. Transl Med. 10 , eaal3973 (2018). A metabolomics approach to decipher the mechanism of action of small-molecule antimicrobial compounds with translational potential .
Rother, M. et al. Combined human genome-wide RNAi and metabolite analyses identify IMPDH as a host-directed target against chlamydia infection. Cell Host Microbe 23 , 661–671.e8 (2018).
Yuan, S. et al. SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target. Nat. Commun. 10 , 120 (2019).
Fontaine, K. A., Sanchez, E. L., Camarda, R. & Lagunoff, M. Dengue virus induces and requires glycolysis for optimal replication. J. Virol. 89 , 2358–2366 (2015).
Article PubMed CAS Google Scholar
Brazma, A. Minimum information about a microarray experiment (MIAME)–successes, failures, challenges. ScientificWorldJournal 9 , 420–423 (2009).
Barrett, T. et al. NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res. 41 , D991–D995 (2013).
Bustin, S. A. et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin. Chem. 55 , 611–622 (2009).
Kahl, G. in The Dictionary of Genomics, Transcriptomics, and Proteomics (Wiley-VCH, 2015).
Sansone, S. A. et al. FAIRsharing as a community approach to standards, repositories and policies. Nat. Biotechnol. 37 , 358–367 (2019). An updated call for FAIR data sharing practices as a community approach to improving scientific research integrity .
Eisenberg, D., Marcotte, E. M., Xenarios, I. & Yeates, T. O. Protein function in the post-genomic era. Nature 405 , 823–826 (2000).
Ma’ayan, A., Blitzer, R. D. & Iyengar, R. Toward predictive models of mammalian cells. Annu. Rev. Biophys. Biomol. Struct. 34 , 319–349 (2005).
Gosak, M. et al. Network science of biological systems at different scales: a review. Phys. Life Rev. 24 , 118–135 (2018).
Ideker, T. & Nussinov, R. Network approaches and applications in biology. PLoS Comput. Biol. 13 , e1005771 (2017).
Wickham, H. Tidy data. J. Stat. Softw. https://doi.org/10.18637/jss.v059.i10 (2014). A fundamental treatise on the clear organization and management of data in modelling and statistics .
Chavan, S. S., Shaughnessy, J. D. Jr. & Edmondson, R. D. Overview of biological database mapping services for interoperation between different ‘omics’ datasets. Hum. Genomics 5 , 703–708 (2011).
Zhang, Y. et al. Influenza research database: an integrated bioinformatics resource for influenza virus research. Nucleic Acids Res. 45 , D466–D474 (2017).
Robertson, D. L. et al. HIV-1 nomenclature proposal. Science 288 , 55–56 (2000).
Parker, T. G., Tindall, B. J. & Garrity, G. M. International Code of Nomenclature of Prokaryotes. Int. J. Syst. Evol. Microbiol. 69 , S1–S111 (2019).
Kim, M. & Tagkopoulos, I. Data integration and predictive modeling methods for multi-omics datasets. Mol. Omics 14 , 8–25 (2018).
D’Argenio, V. The high-throughput analyses era: are we ready for the data struggle? High Throughput 7 , 8 (2018).
Article PubMed Central CAS Google Scholar
Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 , 2498–2504 (2003).
Sarajlic, A., Malod-Dognin, N., Yaveroglu, O. N. & Przulj, N. Graphlet-based characterization of directed networks. Sci. Rep. 6 , 35098 (2016).
Hagberg, A. A., Swart, P. & Schult, D. Exploring network structure, dynamics, and function using NetworkX. in Proc. 7th Python Sci. Conf. (2008).
Huang, S., Chaudhary, K. & Garmire, L. X. More is better: recent progress in multi-omics data integration methods. Front. Genet. 8 , 84 (2017).
Tarca, A. L., Carey, V. J., Chen, X. W., Romero, R. & Draghici, S. Machine learning and its applications to biology. PLoS Comput. Biol. 3 , e116 (2007).
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10 , 1523 (2019).
Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 47 , D607–D613 (2019).
Huang, D. W. et al. The DAVID gene functional classification tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8 , R183 (2007).
Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 , 267–273 (2003).
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102 , 15545–15550 (2005). The first peer-reviewed report of enrichment analysis as a supervised approach for the interpretation of large biological data sets .
Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28 , 27–30 (2000).
Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 , 25–29 (2000). The first report of the widely used Gene Ontology classifications for human genes to allow standardized interpretation and supervised analysis of genetic data sets .
Foulger, R. E. et al. Representing virus-host interactions and other multi-organism processes in the gene ontology. BMC Microbiol. 15 , 146 (2015).
The Gene Ontology Consortium. The gene ontology resource: 20 years and still going strong. Nucleic Acids Res. 47 , D330–D338 (2019).
Kavvas, E. S. et al. Machine learning and structural analysis of Mycobacterium tuberculosis pan-genome identifies genetic signatures of antibiotic resistance. Nat. Commun. 9 , 4306 (2018).
Hofree, M., Shen, J. P., Carter, H., Gross, A. & Ideker, T. Network-based stratification of tumor mutations. Nat. Methods 10 , 1108–1115 (2013).
Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47 , 106–114 (2015).
Cotto, K. C. et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 46 , D1068–D1073 (2018).
Li, Y. H. et al. Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics. Nucleic Acids Res. 46 , D1121–D1127 (2018).
Wishart, D. S. et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46 , D1074–D1082 (2018).
Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92 , 414–417 (2012).
Gaulton, A. et al. The ChEMBL database in 2017. Nucleic Acids Res. 45 , D945–D954 (2017).
Janes, J. et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. Proc. Natl Acad. Sci. USA 115 , 10750–10755 (2018).
Miller, C. H., Nisa, S., Dempsey, S., Jack, C. & O’Toole, R. Modifying culture conditions in chemical library screening identifies alternative inhibitors of mycobacteria. Antimicrob. Agents Chemother. 53 , 5279–5283 (2009).
Couture, J. L., Blake, R. E., McDonald, G. & Ward, C. L. A funder-imposed data publication requirement seldom inspired data sharing. PLoS One 13 , e0199789 (2018).
Alsheikh-Ali, A. A., Qureshi, W., Al-Mallah, M. H. & Ioannidis, J. P. Public availability of published research data in high-impact journals. PLoS One 6 , e24357 (2011).
Vines, T. H. et al. The availability of research data declines rapidly with article age. Curr. Biol. 24 , 94–97 (2014).
Savage, C. J. & Vickers, A. J. Empirical study of data sharing by authors publishing in PLoS journals. PLoS One 4 , e7078 (2009).
Wilkinson, M. D. et al. The FAIR guiding principles for scientific data management and stewardship. Sci. Data 3 , 160018 (2016).
Goncalves, R. S. & Musen, M. A. The variable quality of metadata about biological samples used in biomedical experiments. Sci. Data 6 , 190021 (2019).
Chelliah, V. et al. BioModels: ten-year anniversary. Nucleic Acids Res. 43 , D542–D548 (2015).
Juty, N. et al. BioModels: content, features, functionality, and use. CPT Pharmacomet. Syst. Pharmacol. 4 , e3 (2015).
Pillich, R. T., Chen, J., Rynkov, V., Welker, D. & Pratt, D. NDEx: a community resource for sharing and publishing of biological networks. Methods Mol. Biol. 1558 , 271–301 (2017).
Barrett, T. et al. BioProject and BioSample databases at NCBI: facilitating capture and organization of metadata. Nucleic Acids Res. 40 , D57–D63 (2012).
Courtot, M. et al. BioSamples database: an updated sample metadata hub. Nucleic Acids Res. 47 , D1172–D1178 (2019).
Download references
Acknowledgements
J.F.H. is supported by amfAR grant 109504-61-RKRL with funds raised by generationCURE, the Gilead Sciences Research Scholars Program in HIV, US National Institutes of Health (NIH) grant K22 AI136691, a supplement from the NIH-supported Third Coast Center for AIDS Research (P30 AI117943) and a supplement from the NIH-sponsored HARC Center (P50 AI150476). R.M.K. is supported by the NIH-sponsored HARC Center (P50 AI150476) and the NIH-sponsored Host-Pathogen Mapping Initiative (U19 AI135990). R.H. is supported by the US Department of Defense Advanced Research Projects Agency (HR0011-19-2-0020). N.J.K. is supported by the NIH-sponsored HARC Center (P50 AI150476), the NIH-sponsored Host-Pathogen Mapping Initiative (U19 AI135990), the NIH-sponsored FluOMICs consortium (U19 AI135972) and NIH grant P01 AI063302.
Author information
These authors contributed equally: Manon Eckhardt, Judd F. Hultquist.
Authors and Affiliations
Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA, USA
Manon Eckhardt, Judd F. Hultquist, Robyn M. Kaake, Ruth Hüttenhain & Nevan J. Krogan
Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, CA, USA
J. David Gladstone Institutes, San Francisco, CA, USA
Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
Judd F. Hultquist
You can also search for this author in PubMed Google Scholar
Contributions
M.E., J.F.H, R.M.K. and R.H. researched the literature. M.E., J.F.H, R.M.K., R.H. and N.J.K. wrote the article, provided substantial contributions to discussions of the content and reviewed and/or edited the manuscript before submission.
Corresponding authors
Correspondence to Judd F. Hultquist or Nevan J. Krogan .
Ethics declarations
Competing interests.
The authors declare no competing interests.
Additional information
Peer review information.
Nature Reviews Genetics thanks T. Baumert and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Related links
FAIRsharing: https://fairsharing.org/
Scientific Data recommended data repositories: https://www.nature.com/sdata/policies/repositories
Types of host models that rely on cells taken directly from living tissue (such as from biopsy material or blood) for growth and maintenance ex vivo.
A genetically distinct strain of a pathogen that has been selected for enhanced fitness ex vivo and for use in laboratory experiments even though it is not found as a major strain in the natural world.
Genetic strains of pathogens isolated directly from patients or clinical samples.
Repeated experiments analysing the same sample with the same instrumentation to measure the variability inherent in the testing protocol.
Repeated experiments analysing different samples that represent the same thing (such as samples collected from different patients with the same disease outcome) to determine the variability in the sample pools.
The influence of one or more unmonitored variables on a system’s components or the relationships between those components that can alter experimental interpretation.
A genetic screening technique wherein a codon or set of codons is randomized to produce all possible amino acids at a position or positions.
Iterative rounds of adaptation and counter-adaptation between a pathogen and its host over evolutionary history as a result of the ability of pathogens to elicit selective pressure on their host populations and vice versa.
A method for the random disruption of gene function by the untargeted insertion of transposable retroelements into a genome.
Information that describes a set of data.
The ratio of infectious agents (such as virions or bacteria) to infection targets (such as cells).
A connection point in a network representing a component of the system.
A connection between nodes in a network representing a relationship between two components.
An approach for identifying over-represented classifications of components by comparing the frequency of a given annotation in a data set with a predefined reference list.
A method of data clustering that aims to partition a set of components into a total of k clusters, wherein each component belongs to the cluster with the nearest mean value.
A statistical procedure often used in the development of predictive models, which describes a data set as a series of uncorrelated variables called ‘principal components’ that account for sources of variability.
A machine learning method related to regression analysis that seeks to identify the separation boundary between clusters of data given predefined clusters in a prelabelled set of input data.
A machine learning method that seeks to cluster and classify data on the basis of similarities and differences extracted from a prelabelled set of input data.
A machine learning algorithm that seeks to cluster and classify data on the basis of the ensemble output of a series of decision trees formulated from a prelabelled set of input data.
A measurement of dependency between two variables that is used in machine learning to determine how much can be assumed about one component on the basis of the observed behaviour of another.
Isolation of a given cell population based on an observed trait or characteristic (such as fluorescence or resistance to a toxic compound).
Rights and permissions
Reprints and permissions
About this article
Cite this article.
Eckhardt, M., Hultquist, J.F., Kaake, R.M. et al. A systems approach to infectious disease. Nat Rev Genet 21 , 339–354 (2020). https://doi.org/10.1038/s41576-020-0212-5
Download citation
Accepted : 08 January 2020
Published : 14 February 2020
Issue Date : June 2020
DOI : https://doi.org/10.1038/s41576-020-0212-5
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
Development and psychometric evaluation of nurse’s intention to care for patients with infectious disease scale: an exploratory sequential mixed method study.
- Esmaeil Hoseinzadeh
- Hamid Sharif-Nia
- Abbas Ebadi
BMC Nursing (2024)
Disease outbreak prediction using natural language processing: a review
- Avneet Singh Gautam
Knowledge and Information Systems (2024)
Next-generation proteomics for quantitative Jumbophage-bacteria interaction mapping
- Andrea Fossati
- Deepto Mozumdar
- Danielle L. Swaney
Nature Communications (2023)
Prioritizing non-communicable diseases in the post-pandemic era based on a comprehensive analysis of the GBD 2019 from 1990 to 2019
- Jianhao Shu
- Weifeng Jin
Scientific Reports (2023)
Structure-function analysis of enterovirus protease 2A in complex with its essential host factor SETD3
- Christine E. Peters
- Ursula Schulze-Gahmen
- Nevan J. Krogan
Nature Communications (2022)
Quick links
- Explore articles by subject
- Guide to authors
- Editorial policies
Sign up for the Nature Briefing: Microbiology newsletter — what matters in microbiology research, free to your inbox weekly.
- Search Menu
- Sign in through your institution
- Advance articles
- Editor's Choice
- Supplement Archive
- Cover Archive
- IDSA Guidelines
- IDSA Journals
- The Journal of Infectious Diseases
- Open Forum Infectious Diseases
- Photo Quizzes
- State-of-the-Art Reviews
- Voices of ID
- Author Guidelines
- Open Access
- Why Publish
- IDSA Journals Calls for Papers
- Advertising and Corporate Services
- Advertising
- Journals Career Network
- Reprints and ePrints
- Sponsored Supplements
- Branded Books
- About Clinical Infectious Diseases
- About the Infectious Diseases Society of America
- About the HIV Medicine Association
- IDSA COI Policy
- Editorial Board
- Self-Archiving Policy
- For Reviewers
- For Press Offices
- Journals on Oxford Academic
- Books on Oxford Academic
Editor-In-Chief
Deputy Editors
Associate Editors
Associate Editor/Voices of ID Editor
Associate Editor for Supplements/Methodological and Statistical Editor
Cover Art Editors
Mary Grizzard
Michael Grizzard
Statistical Editors
Ashley L. Buchanan
Steven Cohen
Victor De Gruttola
Farzad Noubary
Histopathology Editors
Jeannette Guarner
Mary Klassen-Fischer
Managing Editor
Katherine Eberenz
Contact for Research Integrity and Publication Ethics Questions
Assistant Managing Editor
Blake Campbell
Supplements Specialist
Special section editors , in the literature.
Stan Deresinski
Photo Quiz/Arcanum
Anthony Amoroso
David J. Riedel
State-of-the-Art Review Editors
Allan R. Tunkel, MD, PhD, MACP
Tara Vijayan, MD
Past Editors
Reviews of infectious diseases.
Edward H. Kass, 1979-1989 (vols. 1-11)
Sydney M. Finegold, 1990-1991 (vols. 12 and 13)
Clinical Infectious Diseases
Sydney M. Finegold, 1992-1999 (vols. 14-29)
Sherwood L. Gorbach, 2000–2016 (vols. 30–63)
Robert T. Schooley, 2017-2022 (vols. 64-74)
Editorial Advisory Board
Brian K. Agan, Bethesda, Maryland
Jan M. Agosti, Seattle, Washington
Samuel L. Aitken, Houston, Texas
Murat Akova, Ankara, Turkey
Michael L. Alkan, Beer Sheva, Israel
David R. Andes, Madison, Wisconsin
Jason R. Andrews, Stanford, California
Spinello Antinori, Milan, Italy
Anucha Apisarnthanarak, Praumthani, Thailand
Ricardo Araujo, Porto, Portugal
Robert D. Arbeit, Boston, Massachusetts
Alejandro Arenas-Pinto, London, United Kingdom
Cesar A. Arias, Houston, Texas
Wendy Armstrong, Atlanta, Georgia
Michael H. Augenbraun, Brooklyn, New York
Paul G. Auwaerter, Baltimore, Maryland
Ritu Banerjee, Nashville, Tennessee
Stephen G. Baum, Bronx, New York
Arnold S. Bayer, Los Angeles, California
Roger J. Bedimo, Dallas, Texas
Robert Belknap, Denver, Colorado
Shalom Ben-Shimol, Beer Sheva, Israel
Jonathan Berman, North Bethesda, Maryland
Gregory P. Bisson, Philadelphia, Pennsylvania
Robert A. Bonomo, Cleveland, Ohio
Louis Bont, Utrecht, Netherlands
Marc J.M. Bonten, Utrecht, Netherlands
Helen W. Boucher, Boston, Massachusetts
David R. Boulware, Minneapolis, Minnesota
William R. Bowie, Vancouver, Canada
Heather Bradley, Atlanta, Georgia
Jared Bullard, Winnipeg, Canada
Steven D. Burdette, Dayton, Ohio
Karen Bush, Bloomington, Indiana
Thomas Butler, Miramar, Florida
André Cabié, Fort-de-France, Martinique
John M. Cafardi, Cincinnati, Ohio
Thomas B. Campbell, Aurora, Colorado
Ann Chahroudi, Atlanta, Georgia
Christina C. Chang, Melbourne, Australia
James D. Cherry, Los Angeles, California
Cheng-Hsun Chiu, Taoyuan, Taiwan
Cornelius J. Clancy, Pittsburgh, Pennsylvania
David B. Clifford, St. Louis, Missouri
Cheryl Cohen, Johannesburg, South Africa
Jonathan A. Colasanti, Atlanta, Georgia
Brian Conway, Vancouver, Canada
Benjamin J. Cowling, Pokfulam, Hong Kong
Ron Dagan, Beer Sheva, Israel
Nick Daneman, Toronto, Canada
Anindita Das, Canberra, Australia
Michael Z. David, Philadelphia, Pennsylvania
Annabelle de St. Maurice, Los Angeles, California
Sarah B. Doernberg, San Francisco, California
Yohei Doi, Pittsburgh, Pennsylvania
Pere Domingo, Barcelona, Spain
Curtis J. Donskey, Cleveland, Ohio
Kelly E. Dooley, Baltimore, Maryland
Robert A. Duncan, Burlington, Massachusetts
Michael W. Dunne, Old Saybrook, Connecticut
John R. Dyer, Perth, Australia
Dean D. Erdman, Atlanta, Georgia
Shelley N. Facente, San Francisco, California
Daniel S. Fierer, New York, New York
William A. Fischer, II, Chapel Hill, North Carolina
Jay A. Fishman, Boston, Massachusetts
Courtney V. Fletcher, Omaha, Nebraska
Anthony R. Flores, Houston, Texas
Nathan Ford, Geneva, Switzerland
Henry S. Fraimow, Camden, New Jersey
Lawrence D. Frenkel, Rockford, Illinois
Alicia M. Fry, Atlanta, Georgia
Luis Furuya-Kanamori, Acton, Australia
Monica Gandhi, San Francisco, California
Jose M. Gatell, Barcelona, Spain
Dale N. Gerding, Hines, Illinois
Sara Gianella Weibel, San Diego, California
Peter H. Gilligan, Chapel Hill, North Carolina
Matthew B. Goetz, Los Angeles, California
Dan M. Granoff, San Francisco, California
David E. Griffith, Tyler, Texas
Carlos G. Grijalva, Nashville, Tennessee
Giovanni Guaraldi, Modena, Italy
Huldrych F. Günthard, Zurich, Switzerland
Colleen Hadigan, Bethesda, Maryland
W. David Hardy, Los Angeles, California
Anthony D. Harris, Baltimore, Maryland
Patrick N.A. Harris, Brisbane, Australia
Rodrigo Hasbun, Houston, Texas
Frederick G. Hayden, Charlottesville, Virginia
Hans H. Hirsch, Basel, Switzerland
Thomas L. Holland, Durham, North Carolina
Edward W. Hook, Birmingham, Alabama
Leigh M. Howard, Nashville, Tennessee
Noreen A. Hynes, Baltimore, Maryland
Michael G. Ison, Chicago, Illinois
Ilesh Jani, Marracuene, Mozambique
Jorgen S. Jensen, Copenhagen, Denmark
Somchai Jongwutiwes, Bangkok, Thailand
Andre C. Kalil, Omaha, Nebraska
Mini Kamboj, New York, New York
Sheldon L. Kaplan, Houston, Texas
Adolf W. Karchmer, Boston, Massachusetts
Carol A. Kauffman, Ann Arbor, Michigan
Colleen F. Kelley, Atlanta, Georgia
James D. Kellner, Calgary, Canada
Brendan J. Kelly, Philadelphia, Pennsylvania
Jeffrey D. Klausner, Los Angeles, California
Keith P. Klugman, Seattle, Washington
Janak Koirala, Springfield, Illinois
Marin H. Kollef, St. Louis, Missouri
Dennis L. Kolson, Philadelphia, Pennsylvania
Shyam Kottilil, Baltimore, Maryland
Peter J. Krause, New Haven, Connecticut
Vincent Le Moing, Montpellier, France
William M. Lee, Dallas, Texas
Jeffrey L. Lennox, Atlanta, Georgia
Emil Lesho, Rochester, New York
Benjamin P. Linas, Boston, Massachusetts
Daniel J. Livorsi, Iowa City, Iowa
Per Ljungman, Stockholm, Sweden
Lisa E. Manhart, Seattle, Washington
Jennifer Manne-Goehler, Boston, Massachusetts
Vincent Marconi, Atlanta, Georgia
Christina M. Marra, Seattle, Washington
Jeanne M. Marrazzo, Birmingham, Alabama
Marianne Martinello, Sydney, Australia
Esteban Martinez, Barcelona, Spain
Henry Masur, Bethesda, Maryland
Kate McCarthy, Brisbane, Australia
Malkanthie I. McCormick, Lexington, Kentucky
Kenneth McIntosh, Boston, Massachusetts
Graeme Meintjes, Cape Town, South Africa
Jean Menotti, Lyon, France
Lynne M. Mofenson, Washington, District of Columbia
Brian T. Montague, Aurora, Colorado
Arnold S. Monto, Ann Arbor, Michigan
David R. Murdoch, Christchurch, New Zealand
Landon Myer, Cape Town, South Africa
Jean B. Nachega, Pittsburgh, Pennsylvania
Kathleen M. Neuzil, Baltimore, Maryland
Valerie L. Ng, Oakland, California
Lindsay E. Nicolle, Winnipeg, Canada
Ran Nir-Paz, Jerusalem, Israel
Amanda Noska, Duluth, Minnesota
Marina Nunez, Winston-Salem, North Carolina
Joseph G. Pastorek, Slidell, Louisiana
Mical Paul, Haifa, Israel
Christopher Payan, Brest, France
Ville Peltola, Turku, Finland
Juan M. Pericas, Barcelona, Spain
Joshua G. Petrie, Ann Arbor, Michigan
Pedro A. Piedra, Houston, Texas
Dylan Pillai, Calgary, Canada
Mathias W. Pletz, Jena, Germany
Raymund R. Razonable, Rochester, Minnesota
Randall R. Reves, Denver, Colorado
John H. Rex, Wellesley, Massachusetts
Frank S. Rhame, Minneapolis, Minnesota
Jurgen K. Rockstroh, Bonn, Germany
William R. Rodriguez, Boston, Massachusetts
Jesús Rodríguez-Baño, Sevilla, Spain
Keith A. Rodvold, Chicago, Illinois
Benjamin A. Rogers, Clayton, Australia
Stephen J. Rogerson, Parkville, Australia
Sarah E. Rowan, Denver, Colorado
Michael S. Saag, Birmingham, Alabama
Lisa Saiman, New York, New York
Max Salfinger, Tampa, Florida
Michael J. Satlin, New York, New York
Mark R. Schleiss, Minneapolis, Minnesota
Audrey N. Schuetz, Rochester, Minnesota
Jennifer E. Schuster, Kansas City, Missouri
John Scott, Seattle, Washington
Edward J. Septimus, Boston, Massachusetts
Irini Sereti, Bethesda, Maryland
Samuel Shelburne, Houston, Texas
Oguz Resat Sipahi, Izmir, Turkey
Graham M. Snyder, Pittsburgh, Pennsylvania
Andrej Spec, St. Louis, Missouri
Brad Spellberg, Los Angeles, California
Sandra A. Springer, New Haven, Connecticut
Serena S. Spudich, New Haven, Connecticut
Jack T. Stapleton, Iowa City, Iowa
Gina A. Suh, Rochester, Minnesota
Mark S. Sulkowski, Baltimore, Maryland
Andrew H. Talal, Buffalo, New York
Paul A. Tambyah, Singapore
Pierre Tattevin, Rennes, France
Elitza Theel, Rochester, Minnesota
Chloe L. Thio, Baltimore, Maryland
David L. Thomas, Baltimore, Maryland
George R. Thompson, Davis, California
Hidenori Toyoda, Ogaki, Japan
Barbara W. Trautner, Houston, Texas
Ephraim L. Tsalik, Durham, North Carolina
Susan Tuddenham, Baltimore, Maryland
Reinout van Crevel, Nijmegen, Netherlands
David van Duin, Chapel Hill, North Carolina
Fernando Vazquez, Oviedo, Spain
Pauline Vetter, Geneva, Switzerland
David H. Walker, Galveston, Texas
Xiu-Feng Wan, Columbia, Missouri
Richard R. Watkins, Akron, Ohio
A. Clinton White, Galveston, Texas
Mark H. Wilcox, Leeds, United Kingdom
Darcy A. Wooten, San Diego, California
Hugh Wright, Brisbane, Australia
Kwok-Yung Yuen, Hong Kong Special Administrative Region, China
Werner Zimmerli, Liestal, Switzerland
- Recommend to your Library
Affiliations
- Online ISSN 1537-6591
- Print ISSN 1058-4838
- Copyright © 2024 Infectious Diseases Society of America
- About Oxford Academic
- Publish journals with us
- University press partners
- What we publish
- New features
- Open access
- Institutional account management
- Rights and permissions
- Get help with access
- Accessibility
- Media enquiries
- Oxford University Press
- Oxford Languages
- University of Oxford
Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide
- Copyright © 2024 Oxford University Press
- Cookie settings
- Cookie policy
- Privacy policy
- Legal notice
This Feature Is Available To Subscribers Only
Sign In or Create an Account
This PDF is available to Subscribers Only
For full access to this pdf, sign in to an existing account, or purchase an annual subscription.
- Latest CDC Covid-19 Info
- CSR Extranet
- Staff Directory
- Contact CSR
For Applicants
CSR’s primary role is to handle the receipt and review of ~ 75% of the grant applications that NIH receives. NIH separates the review process from funding decisions.
For Reviewers
Reviewers are critical to our mission to see that NIH grant applications receive, fair, independent, expert, and timely scientific reviews. We appreciate the generosity with which reviewers give their time.
News & Policy
The latest news and policy updates from CSR. Read about our outreach programs and publications.
- Study Sections
Applications are reviewed in study sections (Scientific Review Group, SRG). Review Branches (RBs) are clusters of study sections based on scientific discipline.
Review Panels & Dates
Evaluating panel quality in review (enquire), enquire overview.
- Cluster Overview Process
Clusters Evaluated via ENQUIRE
ENQUIRE Overview Cluster Overview Process Clusters Evaluated via ENQUIRE
Science changes rapidly. Making sure that study sections change with the science is an ongoing challenge. CSR ENQUIRE integrates data and input from multiple stakeholders to determine whether changes in study section focus or scope are needed to facilitate the identification of high impact science, with special consideration of emerging science.
Words from Dr. Noni Byrnes, CSR Director
Science-based Clusters of study sections are formed based on scientific topics (instead of CSR managerial units) for review via ENQUIRE
Systematic, data-driven, continuous process ~20% of CSR study sections are evaluated each year, every study section evaluated every 5 years
Stakeholder input and involvement External scientific community, extramural programs at NIH, CSR staff
Iterative Approach Continuous refinement of the process based on experience
Critical to success Matching referral of applications and reviewer expertise to redefined scientific scope of study sections
Multiple Possible Actions Follow
- Change in scientific guidelines
- Merge study sections
- Create new study sections
- Redistribute areas across study sections
- Add emerging areas of science
- Eliminate study sections
- current scientific guidelines
- sample abstracts & aims
- data on workload trends, bibliometric output, ESI submission and success rates
- workload data
- scoring trends
- survey feedback from reviewers & program officers
- site-visit information on meeting function
- External Scientific Working Group’s report
- CSR Advisory Council
- NIH Office of the Director
- Test practicality of new guidelines through mock application referral
- Reassignment of standing study section members to fit guidelines of new study sections
- Publicize new study sections to the community
- Monitor referral & adherence to new guidelines
Brain Disorders: Clinical, Translational, and Neurotechnology
Immunology and respiratory systems, drug synthesis, discovery, disposition, and xenobiotics, microbiology and infectious diseases, epidemiology and population sciences, molecular and cellular basic sciences, healthcare delivery/patient outcomes, gi, renal, endocrine systems, cardiac, vascular and hematologic sciences, functional/cognitive neuroscience, clusters evaluated via enquire in 2023, study sections evaluated (12).
- Acute Neural Injury and Epilepsy ANIE
- Adult Psychopathology and Disorders of Aging APDA
- Aging Systems and Geriatric Study Section ASG
- Bioengineering of Neuroscience, Vision Technologies BNVT
- Clinical Neuroimmunology and Brain Tumors CNBT
- Clinical Neuroscience and Neurodegeneration CNN
- Child Psychopathology and Developmental Disabilities CPDD
- Developmental Brain Disorders DBD
- Emerging Imaging Technologies in Neuroscience EITN
- Neural Basis of Psychopathology, Addictions, and Sleep Disorders NPAS
- Noninvasive Neuromodulation and Neuroimaging Technologies ETTN 91
- Vision Imaging, Bioengineering, and Low Vision Technology Development ETTN 81 (BIVT)
Resulting Study Sections (14)
- Adult Lifespan Psychopathology ALP
- Brain Injury and Neurovascular Disorders BIND
- Bioengineering and Tissue Engineering for Neuroscience BTEN
- Cognitive Disorders and Brain Aging CDBA
- Clinical Neurodegeneration Translational Neuroscience CNTN
- Imaging and Bioengineering Technology for Visual Systems (recurring SEP) IBV
- Imaging Technologies in Neuroscience ITN
- Neuro Informatic, Computational and Data Analysis (recurring SEP) NICD
- Neuromodulation and Imaging of Neuronal Circuits NINC
Study Sections Evaluated (10)
- Arthritis, Connective Tissue and Skin ACTS
- Cellular and Molecular Immunology A CMIA
- Cellular and Molecular Immunology B CMIB
- Hypersensitivity, Autoimmune, and Immune-mediated Diseases HAI
- Hypersensitivity, Allergies and Mucosal Immunology IIDB (57)
- Innate Immunity and Inflammation III
- Lung Cellular, Molecular, and Immunobiology LCMI
- Lung Injury, Repair, and Remodeling LIRR
- Respiratory Integrative Biology and Translational Research RIBT
- Transplantation, Tolerance and Tumor Immunology TTT
Resulting Study Sections (12)
- Adaptive Immunity AI
- Innate Immunity A ZRG1 IIDA (81)
- Innate Immunity B IIB
- Immune Mechanisms of Hypersensitivity and Allergy IMHA
- Immunobiology of Transplantation and Alloimmunity ITA
- Lung Immunology and Infection LII
- Mechanisms of Autoimmunity MAI
- Molecular and Structural Immunology MSI
- Pulmonary Injury Remodeling and Repair PIRR
- Pulmonary Vascular Disease and Physiology PVP
- Skin and Connective Tissue Sciences SCTS
- Translational Investigations of Pulmonary and Immunological Diseases ZRG1 RCCS (81)
Clusters Evaluated via ENQUIRE in 2022
Study sections evaluated (14).
- Cancer Etiology CE
- Drug Discovery for the Nervous System DDNS
- Drug Discovery and Mechanisms of Antimicrobial Resistance DDR
- Drug Discovery and Molecular Pharmacology DMP
- Developmental Therapeutics DT
- Gene and Drug Delivery Systems GDD
- Nanotechnology NANO
- Synthetic and Biological Chemistry A SBCA
- Synthetic and Biological Chemistry B SBCB
- Systemic Injury by Environmental Exposure SIEE
- Xenobiotic and Nutrient Disposition and Action XNDA
- Topics in Bacterial Pathogenesis ZRG1 AIDC (82)
- Eukaryotic Pathogen Drug Discovery and Resistance ZRG1 AIDC (83)
- PAR Panel: High Throughput Screening ZRG1 BST-F (55)
- Anti-Infective Resistance and Targets AIRT
- Advancing Therapeutics A ATA
- Advancing Therapeutics ZRG1 MCST (81)
- Chemical Biology & Probes CBP
- Chemical Synthesis & Biosynthesis CSB
- Drug and Biologic Disposition and Toxicity DBDT
- Drug and Biologic Therapeutic Delivery DBTD
- Drug Discovery and Molecular Pharmacology A DMPA
- Drug Discovery and Molecular Pharmacology DCAI (81)
- Drug Discovery and Molecular Pharmacology C DMPC
- Drug Discovery and Molecular Pharmacology B DMPB
- Environmental Determinants of Disease EDD
- Innovations in Nanosystems and Nanotechnology INN
- Nucleic Acid Therapeutic Delivery BBBT (81)
- Bacterial Pathogenesis BACP
- Host Interactions with Bacterial Pathogens HIBP
- Immunity and Host Defense IHD
- Prokaryotic Cell and Molecular Biology PCMB
- Pathogenic Eukaryotes PTHE
- Vector Biology VB
- Vaccines Against Microbial Diseases VMD
- Virology - A VIRA
- Virology - B VIRB
- Topics in Bacterial Pathogenesis ZRG1 IIDA-B 80
Resulting Study Sections (11)
- Bacterial-Host Interactions BHI
- Bacterial Virulence BV
- Interspecies Microbial Interactions and Infections IMII
- Molecular and Cellular Biology of Virus Infection MCV
- Transmission of Vector-Borne and Zoonotic Diseases TVZ
- Viral Dynamics and Transmission VDT
- Vaccines Against Microbial Diseases VID
- Viral Pathogenesis and Immunity VPI
Study Sections Evaluated (9)
- Behavioral Genetics and Epidemiology BGES
- Biostatistical Methods and Research Design BMRD
- Cancer, Heart, and Sleep Epidemiology Panel A CHSA
- Cancer, Heart, and Sleep Epidemiology Panel B CHSB
- Clinical Research and Field Studies of Infectious Diseases CRFS
- Genetics of Health and Disease GHD
- Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions IRAP
- Kidney, Nutrition, Obesity and Diabetes KNOD
- Neurological, Aging and Musculoskeletal Epidemiology NAME
Resulting Study Sections (13)
- Aging, Injury, Musculoskeletal, and Rheumatologic Disorders AIMR
- Analytics and Statistics for Population Research Panel A ASPA
- Analytics and Statistics for Population Research Panel B ASPB
- Cancer and Hematologic Disorders CHD
- Cardiovascular and Respiratory Diseases CRD
- Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases EDIT
- Kidney, Endocrine, and Digestive Disorders KEDD
- Lifestyle and Health Behaviors LHB
- Neurological, Mental and Behavioral Health NMBH
- Population-based Research in Infectious Disease PRID
- Reproductive, Perinatal, and Pediatric Health RPPH
- Social and Environmental Determinants of Health SEDH
- Cancer Molecular Pathobiology CAMP
- Cancer Biomarkers CBSS
- Cancer Immunopathology and Immunotherapy CII
- Clinical Oncology CONC
- Mechanisms of Cancer Therapeutics - 1 MCT1
- Mechanisms of Cancer Therapeutics - 2 MCT2
- Molecular Oncogenesis MONC
- Tumor Cell Biology TCB
- Tumor Microenvironment TME
- Tumor Progression and Metastasis TPM
- Biochemical and Cellular Oncogenesis BCO
- Cancer Cell Biology CCB
- Cellular Immunotherapy of Cancer CIC
- Gene Regulation in Cancer GRIC
- Molecular Cancer Diagnosis and Classification MCDC
- Mechanisms of Cancer Therapeutics A MCTA
- Mechanisms of Cancer Therapeutics B MCTB
- Mechanisms of Cancer Therapeutics C MCTC
- Tumor Evolution, Heterogeneity and Metastasis TEHM
- Tumor Host Interactions THI
- Translational Immuno-oncology TIO
- Therapeutic Immune Regulation TIR
Clusters Evaluated via ENQUIRE in 2021
Study sections evaluated (16).
- Biochemistry and Biophysics of Membranes BBM
- Biophysics of Neural Systems BPNS
- Cellular Signaling and Regulatory Systems CSRS
- Membrane Biology and Protein Processing MBPP
- Molecular Genetics A MGA
- Molecular Genetics B MGB
- Molecular and Integrative Signal Transduction MIST
- Molecular Neuropharmacology and Signaling MNPS
- Macromolecular Structure and Function A MSFA
- Macromolecular Structure and Function B MSFB
- Macromolecular Structure and Function C MSFC
- Macromolecular Structure and Function D MSFD
- Nuclear and Cytoplasmic Structure/Function and Dynamics NCSD
- Neurotransporters, Receptors, and Calcium Signaling NTRC
- Synapses, Cytoskeleton and Trafficking SYN
- Cell Structure and Function-1 CSF-1
- Cell Structure and Function-2 CSF-2
- Molecular Cellular Neuropharmacology MCNP
- Molecular Genetics MG
- Neuronal Communications NC
- Receptor Biology and Signal Transduction RBST
Clusters Evaluated via ENQUIRE in 2019
- Biomedical Computing and Health Informatics BCHI
- Behavioral Medicine: Interventions and Outcomes BMIO
- Community-Level Health Promotion CLHP
- Clinical Management of Patients in Community-based Settings CMPC
- Dissemination and Implementation Research in Health DIRH
- Health Disparities and Equity Promotion HDEP
- Health Services Organization and Delivery HSOD
- Nursing and Related Clinical Sciences NRCS
- Psychosocial Risk and Disease Prevention PRDP
- Biobehavioral Medicine and Health Outcomes BMHO
- Clinical Data Management and Analysis CDMA
- Clinical Informatics and Digital Health CIDH
- Clinical Management in General Health Care Settings CMGC
- Healthcare and Health Disparities HHD
- Health Promotion in Communities HPC
- Health Services: Quality and Effectiveness HSQE
- Interdisciplinary Clinical Care in Specialty Care Settings ICSC
- Lifestyle Change and Behavioral Health LCBH
- Organization and Delivery of Health Services ODHS
- Science of Implementation in Health and Healthcare SIHH
Study Sections Evaluated (11)
- Cellular Aspects of Diabetes and Obesity CADO
- Clinical and Integrative Diabetes and Obesity CIDO
- Clinical, Integrative and Molecular Gastroenterology CIMG
- Gastrointestinal Mucosal Pathobiology GMPB
- Hepatobiliary Pathophysiology HBPP
- Integrative Nutrition and Metabolic Processes INMP
- Integrative Physiology of Obesity and Diabetes IPOD
- Kidney Molecular Biology and Genitourinary Organ Development KMBD
- Molecular and Cellular Endocrinology MCE
- Pathobiology of Kidney Disease PBKD
- Urology and Urogynecology ZRG1 DKUS 90
Resulting Study Sections (10)
- Basic Mechanisms of Diabetes and Metabolism BMDM
- Cell Signaling and Molecular Endocrinology CSME
- Digestive System Host Defense, Microbial Interactions and Immune and Inflammatory Disease DHMI
- Digestive and Nutrient Physiology and Diseases DNPD
- Human Studies of Diabetes and Obesity HSDO
- Kidney and Urological Systems Function and Dysfunction KUFD
- Nutrition and Metabolism in Health and Disease NMHD
- Pathophysiology of Obesity and Metabolic Disease POMD
- Atherosclerosis and Inflammation of the Cardiovascular System AICS
- Cardiac Contractility, Hypertrophy, and Failure CCHF
- Clinical and Integrative Cardiovascular Sciences CICS
- Electrical Signaling, Ion Transport, and Arrhythmias ESTA
- Hemostasis and Thrombosis HT
- Hypertension and Microcirculation HM
- Molecular and Cellular Hematology MCH
- Myocardial Ischemia and Metabolism MIM
- Vascular Cell and Molecular Biology VCMB
- Transfusion Medicine Sep ZRG1 VH-D 55
Resulting Study Sections (8)
- Atherosclerosis and Vascular Inflammation AVI
- Basic Biology of Blood, Heart and Vasculature BBHV
- Clinical Integrative Cardiovascular and Hematological Sciences CCHS
- Hemostasis, Thrombosis, Blood Cells and Transfusion HTBT
- Integrative Vascular Physiology and Pathology IVPP
- Integrative Myocardial Physiology/Pathophysiology A MPPA
- Integrative Myocardial Physiology/Pathophysiology B MPPB
- Therapeutic Development and Preclinical Studies TDPS
- Auditory System AUD
- Biology of the Visual System BVS
- Cognition and Perception CP
- Chemosensory Systems CSS
- Diseases and Pathophysiology of the Visual System DPVS
- Neurobiology of Learning and Memory LAM
- Language and Communication LCOM
- Neuroendocrinology, Neuroimmunology, Rhythms and Sleep NNRS
- Sensory Motor Integration SMI
- Mechanisms of Sensory, Perceptual, and Cognitive Processes SPC
- Somatosensory and Pain Systems SPS
- Ocular Surface, Cornea, Anterior Segment Glaucoma, and Refractive Error Special Emphasis Panel ZRG1 BDCN-J 81
- Auditory Systems AUD
- Biology and Development of the Eye BDE
- Behavioral Neuroendocrinology, Neuroimmunology, Rhythms, and Sleep BNRS
- Human Complex Mental Function HCMF
- Learning, Memory and Decision Neuroscience LMDN
- Neuroscience of Basic Visual Processes NBVP
- Neuroscience of Interoception and Chemosensation NIC
- Neurobiology of Pain and Itch NPI
- Pathophysiology of Eye Disease 1 PED1
- Pathophysiology of Eye Disease 2 PED2
- Sensory-Motor Neuroscience SMN
Last updated: 09/29/2023 12:31
- More Social Media from NIH
Switching Role/Affiliation
- Manage Preferences
STUDY SECTION ROSTER INFORMATION
Study Section | Membership Roster | Committee Name | SRO (E-MAIL) | Meeting Rosters |
---|---|---|---|---|
No meeting rosters. |
Clinical Program Leader
About the role.
Your responsibilities will include but are not limited to: • Acts as a clinical leader responsible for assigned global clinical program(s) -driving medical strategy implementation and operational deliverables for investigational products in a defined therapeutic area • Ensure effective cross-functional communications to align with global strategy and leads the development of clinical sections of trial and program level regulatory documents
• Acts as the medical expert, engages interactions with external stakeholders (e.g., regulatory authorities, key opinion leaders, data monitoring committees, advisory boards etc.) and internal NVS stakeholders • Contributes to medical/scientific training of relevant Novartis stakeholders. May serve as speaker for medical/scientific training -May serve on or lead global initiatives (e.g., process improvement, training, SOP development, other Clinical Development line function initiatives) • Experience leading early and/or late phase Oncology clinical programs from the pharma/biotech industry plus credible experience from an academic medical center. In case of no industry experience then significant academic experience with credible PI/co-PI clinical study leadership • Track record of significant contributions to your field over time, creating new concepts and seeking out new clinical discovery opportunities / approaches
Role Requirements:
Medical degree, oncology board certified preferred, and PhD level basic Science or equivalent expertise ∙ ≥ 3 years technical, operational and managerial experience in planning, executing, reporting and design of clinical trials studies in a pharmaceutical company, academic centre or contract research organisation ∙ Good knowledge of Good Clinical Practice, clinical trial design, statistics, regulatory processes, and global clinical development process ∙ Good knowledge of oncology and experience in early clinical development preferred. ∙ Good communication, writing and organization and skills, fluent in English written and spoken
Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture
Join our Novartis Network: Not the right Novartis role for you? Sign up to our talent community to stay connected and learn about suitable career opportunities as soon as they come up: https://talentnetwork.novartis.com/network
Benefits and Rewards: Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: https://www.novartis.com/careers/benefits-rewards
Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.
Epidemiology in the Division of Intramural Research
Epidemiology is a core science in public health that includes surveillance, observation, hypothesis testing, analytic research, and experiments and interventions. As the fundamental science of preventive medicine and public health, epidemiology has traditionally focused on disease causation through population studies. Epidemiologists develop and evaluate hypotheses about the effects of genetic, behavioral, environmental, and healthcare factors on human health and develop the knowledge bases for disease prevention and control programs. The field is interdisciplinary and has a methodology distinct from, but dependent on, biostatistics. Epidemiologists incorporate into their research the knowledge base and tools of other disciplines including the biologic sciences, clinical research, and other population sciences.
Main Areas of Focus
While our primary efforts focus on leading research relating to different aspects of infectious disease epidemiology and public health, epidemiologists at NIAID support research of relevance to the mission of NIAID, with approaches that include the following:
- Design of clinical and population-based studies with appropriate methods and sampling strategies, focusing on reducing study bias and improving data collection
- Analysis of randomized and non-randomized study cohorts using multivariable methods to identify host and pathogen contributions to infection and disease
- Application of machine learning and other data science tools to study disease risk factors for selected infectious diseases and immune disorders
- Molecular techniques to investigate immunological responses to emerging and re-emerging viral diseases
- Research areas of particular interest include emerging viral pathogens, antimicrobial resistance, nontuberculous mycobacteria, malaria, SARS-CoV-2, Ebola, invasive fungal infections, inborn errors of immunity
Contact Information
Leah Katzelnick, Ph.D, M.P.H. – Seroepidemiology
Jennifer Kwan, Ph.D. – Infectious disease epidemiology, geospatial statistics
Rebecca Prevots, Ph.D. – Epidemiology of nontuberculous mycobacteria
Emily Ricotta, Ph.D., M.Sc. – Infectious disease epidemiology, data management
IMAGES
VIDEO
COMMENTS
Scientific Review Officer. [email protected]. 301-257-2638. The Population-based Research in Infectious Disease Study Section (PRID) study section reviews applications that characterize the incidence, transmission, and prevention of infectious diseases in human populations through identification of the determinants, predictors, and ...
The Etiology, Diagnostic, Intervention and Treatment of Infectious Diseases (EDIT) study section reviews translational and applied applications that address the emergence, diagnosis, surveillance and control of infectious diseases that affect humans. ... Clinical studies and field research for the development and evaluation of treatment and ...
Established in 1942, the Laboratory of Infectious Diseases (LID) has a long history of vaccine development and identification of new agents of viral diseases. LID is noted for undertaking high-risk, high-re ward programs that require extraordinary time and resource commitments, such as programs to develop vaccines for viral hepatitis, severe ...
Dr. Jian Wang. Scientific Review Officer. [email protected]. 301-827-3396. The Vaccines Against Infectious Diseases (VID) Study Section reviews applications concerned with vaccine development against all classes of pathogens (except HIV). A feature of applications reviewed in this study section is the measurement of vaccine efficacy or ...
Below are current clinical trials. 24 studies in Infectious Diseases (open studies only). ... The general aim of this study is to estimate the rate of disease progression for adults who seek testing and test positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day ...
The Division of Infectious Diseases participates in graduate programs and research in microbiology and molecular genetics, immunology and molecular pathogenesis, as well as population biology, ecology, and evolution. Additional opportunities are available for basic science research in: Toxin-mediated infections. Intracellular pathogens. Influenza.
Here, we review a systems biology approach to infectious disease in three phases: discovery, representation and application ( FIG. 2 ). Rather than focus on a specific technique or pathogen, this Review outlines a broad, universal framework for systems biology through the lens of infectious disease research.
The only study guide that is current on basic infections disease fundamentals. Written by experts in both adult and pediatric infections. Each chapter follows a consistent format for ease of use. Can serve as a standalone book or as a complement to a larger book accompanying a course, such as Introduction to Clinical Infectious Diseases.
Heinz Feldmann, M.D., Ph.D., Chief. The Laboratory of Virology (LV) conducts innovative scientific research on viral agents requiring high or maximum containment (biosafety level-2 to biosafety level-4). These agents include filoviruses, bunyaviruses, arenaviruses, and flaviviruses. Research studies focus on vector/reservoir transmission, viral ...
This Review outlines a broad, universal framework for systems biology applied to infectious disease research. From study design and omics data collection, analysis, visualization and ...
The VTEUs are located at institutions across the United States. They conduct Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners. Depending on the disease or condition, the VTEUs may establish study sites and enroll participants at locations outside the United States.
All studies must contribute insights into infectious diseases of humans and their public health impact. Clinical trials, clinical case reports/series, and other clinically relevant studies do not fall within the scope of this section and may be appropriate for other Frontiers sections, including Infectious Diseases in Frontiers in Medicine. Facts
The Section of Infectious Diseases and Global Health has recently increased staffing to 16 full time faculty, with a commitment from the Department of Medicine to continue expansion and expand capacity for basic laboratory investigation. Although a small group, the special interests and expertise of the faculty are quite complimentary.
The field of mathematical and statistical modeling of infectious diseases is well established [5, 54, 55] as is, of course, epidemiology and clinical trial methodology. When a pandemic suddenly breaks out, all of these areas are strongly forced to collaborate, whereas scientific areas, even within medicine, tend to be compartmentalized.
London: Academic Press, 2014. 420 pp. $150.00 (hardcover). ISBN:978--12-416975-3. Emerging Infectious Diseases: Clinical Case Studies is an easy-to-use, extraordinarily informative text that belongs on every clinician's shelf. A collaborative effort among scientists, clinicians, and public health workers is needed to combat emerging infections.
The goal of this research is to characterize the mucosal microbiome in patients with CDI after treatment to characterize this microbiome and determine the effect on recurrence of CDI. A Study to Analyze Algorithms for Evaluating Early Detection of SARS-CoV/COVID-19 Infection in Critical Service Employees Rochester, MN.
His clinical and research interests center on important infections of childhood, including vaccine-preventable diseases. Dr. Ratner has served as chair of the Clinical Research and Field Studies in Infectious Diseases study section at NIH and as a member of the Board of Directors of the Pediatric Infectious Diseases Society.
The priority afforded to infectious diseases within epidemiologic research has been fluid over the past 200 years or longer. Despite the lasting prominence of early investigations into measles, cholera, plague, typhoid fever, malaria, and yellow fever (1-6), the intellectual tradition of modern epidemiology stems largely from studies of chronic diseases dating to the post-World War II era ...
This section aims at strengthening and appraising the evidence base to inform clinical practice and improve infectious disease management and therapy. This section will publish research advances that unravel the mechanisms and biological determinants of human infections, host-pathogen interaction and disease pathogenesis at experimental and ...
Evaluating Panel Quality in Review (ENQUIRE) Science changes rapidly. Making sure that study sections change with the science is an ongoing challenge. CSR ENQUIRE integrates data and input from multiple stakeholders to determine whether changes in study section focus or scope are needed to facilitate the identification of high impact science ...
During the next few days, the Division of Receipt and Referral (DRR) in NIH's Center for Scientific Review will update this information with the study section assignment. If you don't see your study section assignment within 2 weeks, call DRR at 301-435-0715. For more on this topic, read Application Assigned to a Review Group.
CRFS. VIEW. CLINICAL RESEARCH AND FIELD STUDIES OF INFECTIOUS DISEASES STUDY SECTION. LI, JAMES J. No meeting rosters. eRA - End-to-End Grants Management Solutions. NIH Grants and Funding. National Institutes of Health. HHS - U.S. Dept. of Health and Human Services.
Your responsibilities will include but are not limited to:• Acts as a clinical leader responsible for assigned global clinical program(s) -driving medical strategy implementation and operational deliverables for investigational products in a defined therapeutic area• Ensure effective cross-functional communications to align with global strategy and leads the development of clinical ...
Epidemiology is a core science in public health that includes surveillance, observation, hypothesis testing, analytic research, and experiments and interventions. As the fundamental science of preventive medicine and public health, epidemiology has traditionally focused on disease causation through population studies. Epidemiologists develop and evaluate hypotheses about the effects of genetic ...